Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886831 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
A Phase 1 study, sponsored by Prelude Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
NCT03886831 is a Phase 1 study that has completed, run by Prelude Therapeutics. The registered enrollment target is 232 participants.
The verdict
NCT03886831, a Phase 1 study, has completed, sponsored by Prelude Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
Study Summary
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
Interventions
- DRUG PRT543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03886831
The ClinicalTrials.gov registry entry for NCT03886831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT543 is the first listed.
NCT03886831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03886831 about?
NCT03886831 is a clinical study titled "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies". This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
What is the current status of trial NCT03886831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2019-02-11. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT03886831?
The interventions under investigation include: PRT543 (DRUG).
Who is sponsoring clinical trial NCT03886831?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.